Lilly: &#39;05 Profit Driven by Newer Drugs
496920
Eli Lilly and Co. (LLY.N: Quote, Profile, Research) on Thursday said it expects 2005 earnings to rise as higher sales of its newer drugs offset a decline in its top-selling schizophrenia drug Zyprexa.
353925
Eli Lilly and Co. LLY.N on Wednesday  reported a fourth-quarter net loss on charges for restructuring  and taxes related to the return of overseas profits as sales of  prescription drugs rose only slightly.
540408
Fourth-quarter profit surged from a year-ago period that included hefty restructuring costs and liability charges related to the companyâs top-selling drug, Zyprexa.
641779
Schering-Plough Corp.  on  Monday reported quarterly earnings far higher than Wall Street  expected, fueled by growing demand for its drugs against  cholesterol, arthritis, allergies and hepatitis C.
705384
Drugmaker Eli Lilly and Co. (LLY.N: Quote, Profile, Research) on Wednesday said it will make clinical trial information available online amid calls by lawmakers and physicians for more disclosure of negative trial results.
34149
Eli Lilly and Co.  on Friday  reported strong second-quarter earnings, fueled by strong  revenue growth of newer drugs, including an almost doubling of  sales for its Cymbalta depression treatment.
740587
Eli Lilly and Co. LLY.N on Thursday  said its third-quarter earnings rose as a drop in sales of its  best selling schizophrenia medication was offset by demand for  drugs to treat depression and impotence.
535789
Net profit at Roche Holding  AG  rose 34 percent to 9.17 billion Swiss francs ($7.33  billion) in 2006 due to strong sales of cancer treatments  Herceptin and Avastin, just ahead of analysts' expectations.
597737
Eli Lilly posted better-than-expected second-quarter earnings, helped by surging sales of its prescription drugs, and the company raised its 2007 profit forecast.
245874
Eli Lilly and Co.  said on Thursday it is on track to meet its 2006 growth forecast of 8 percent to 12 percent, but projected slower profit growth in 2007 though its revenues will grow at a faster pace next year.
294964
The British pharmaceuticals giant GlaxoSmithKline announced a nine percent drop in annual pretax profits which were hit by sales of generic drugs and a weaker dollar, but the group looked ahead to a strong 2005.
548512
Walgreen Co. WAG.N on Monday posted a  30.5 percent rise in quarterly profit, boosted by sales of  generic drugs and digital photo processing, sending its shares  to a nearly three-year high.
14948
Merck & Co. Inc.MRK.N, reeling from  the recent withdrawal of its Vioxx arthritis drug, said  Wednesday it expects 2005 earnings of $2.42 to $2.52 a share --  a decline from expected 2004 results.
312721
The biotechnology company reported fourth-quarter net income of $201.2 million on strong sales of its two leading drugs, Rituxan and Avonex.
280448
Pfizer Inc., the world's largest drug company, said Wednesday that its net income for the fourth quarter more than quadrupled, driven by strong sales of cholesterol drug Lipitor. Its earnings missed analysts' forecasts after excluding certain items, however.
686673
Eli Lilly and Co.  said on Wednesday fourth-quarter earnings fell, hurt by a charge for a settlement with users of its Zyprexa schizophrenia drug, and the company forecast 2007 earnings at the low end of Wall Street estimates.
762552
Its sales were up for the quarter, but a new drug might be the best indicator of its prospects.